Navigation Links
Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
Date:7/19/2010

) and headache (tapentadol ER, 13.3; oxycodone CR, 7.6). In the tapentadol ER and oxycodone CR groups, respectively, TEAEs led to discontinuation in 22.1 percent and 36.8 percent of patients.

Chronic pain, affecting an estimated 100 million Americans, continues to be a significant medical challenge in the United States. Osteoarthritis pain and low back pain are particularly prevalent – osteoarthritis pain affects 27 million Americans, and chronic low back pain is the most common cause of disability in developed countries.

Although currently available long-acting opioid analgesics have been shown to provide relief for moderate to severe chronic pain, many are associated with high incidences of side effects, which can cause patients to discontinue their treatment. Research also shows that physicians are uncomfortable prescribing opioids due to these opioid-related side effects.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) and Grunenthal GmbH, conducted this study, which J&JPRD has included as part of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol ER tablets for the management of moderate to severe chronic pain in patients 18 years of age or older. The FDA currently is reviewing this application and, if approved, PriCara®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., will market tapentadol ER in the United States.

The full article in Pain Practice can be accessed online at http://www3.interscience.wil
'/>"/>

SOURCE PriCara
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 02, 2015 Research and ... of the "The Future of Pharmaceutical Outsourcing" ... they are in a desperate need to develop ... cost, drug companies have been increasingly utilizing external ... productivity while constantly streamlining their internal operation. Their ...
(Date:6/3/2015)... SHANGHAI , June 3, 2015 MEDTEC China South ... an extension of MEDTEC China 2015, MEDTEC China South has ... attributes, standing out as a key event for the medical ... After many years of challenges, this year marks the successful return ... 10 years after the event first debuted there in 2005. ...
(Date:6/3/2015)... , June 3, 2015 Genoa ... Pharmaceuticals, Inc., bringing together two pharmacy organizations with proven ... illness. Both companies have strong reputations for outstanding customer ... Genoa is the ... health community and those affiliated with managing the cost ...
Breaking Medicine Technology:The Future of Pharmaceutical Outsourcing: 2015 Report 2MEDTEC Successfully Returns to Southern China 2MEDTEC Successfully Returns to Southern China 3Genoa, a QoL Healthcare Company Acquires Northeast Pharmaceuticals, Inc. 2
... , MORRISTOWN, N.J. , March 11 ... today announced the U.S. Food and Drug Administration (FDA) ... suspension), a new twice-yearly formulation of TRELSTAR®, a proven, ... With an anticipated May launch, TRELSTAR® 22.5 mg is ...
... , THOUSAND OAKS, Calif. , March 11 ... has received a US Patent Office Notice of Allowance ... expressing, secreting, and purifying the NELL-1 sequence of the ... a Chinese hamster ovary (CHO) cell. This patent continues ...
Cached Medicine Technology:FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process 2Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process 3
(Date:6/3/2015)... 03, 2015 blingsting announces their new ... car's glove compartment or can be strapped onto a ... features a pointed tip that will allow the user ... blade that can cut through a seatbelt or carseat ... Glammer include:, ,         Easily break a window ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 EMBARGOED FOR RELEASE ... Birth Weight Associated with Proximity of Mother’s Home to Gas ... close to a high density of natural gas wells drilled ... lower birth weights than women living farther from such wells, ... Public Health analysis of southwestern Pennsylvania birth records. ...
(Date:6/3/2015)... The Canton Group, a leading web ... announced today that Tim Dodge has joined the company ... The Canton Group as it implements an ambitious ... , Tim is a tech industry veteran who has ... technology companies. Before joining The Canton Group, Tim was ...
(Date:6/3/2015)... June 03, 2015 On the heels of ... billion industry by 2020 ( click here to review ... scientists believe Baltimore has the talent to become ... which genetic code and other biological data are collected and ... “Baltimore contains all the elements of a perfect storm ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Alberto Grignolo, ... at DIA’s upcoming Annual Meeting. DIA’s Global Inspire Award ... level of excellence, and commitment to service on a ... Global Connector Award that annually recognizes one DIA member ... advanced the mission of DIA to foster innovation to ...
Breaking Medicine News(10 mins):Health News:blingsting Announces All New Car Safety Tool The Glammer 2Health News:Fracking Proximity Associated with Lower Birth Weight 2Health News:Fracking Proximity Associated with Lower Birth Weight 3Health News:Fracking Proximity Associated with Lower Birth Weight 4Health News:The Canton Group Appoints Tim Dodge as Chief Marketing Officer 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 2Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 3
... variety of therapeutic categories can be screened to identify effective ... for publication in the Endocrine Society,s Journal of Clinical ... rapidly be implemented into a clinical trial to test how ... chemical agents capable of modulating a disease is a long ...
... trial found that rilonacept, an inhibitor of the ... that occur when initiating uric acid-lowering therapy. Results ... targeted therapy in prevention of gout flaresshow rilonacept ... infections or treatment-related serious adverse events reported. Full ...
... WEDNESDAY, Jan. 4 (HealthDay News) -- Nearly one in four ... that her risk of getting other sexually transmitted diseases is ... commonly transmitted sexually transmitted infection (STI) in the United States, ... to 19 infected. Some virus types can raise the ...
... women against infection from one of the two types of herpes ... New England Journal of Medicine . The vaccine was ... did not protect women from herpes simplex virus type 2 (HSV-2). ... herpes caused by HSV-1 58 percent fewer -- in women ...
... By Mary Brophy Marcus HealthDay Reporter , ... against the hepatitis C virus, which can cause severe liver ... it,s likely years away, researchers are reporting. , , There ... estimated 170 million people worldwide. , , Like HIV, the ...
... (HealthDay News) -- New research shows that women with ... from depression and so-called "disordered eating," regardless of whether ... that most [study] participants frequently adhered to a gluten-free ... to increased vitality, lower stress, decreased depressive symptoms and ...
Cached Medicine News:Health News:New drug screening identifies chemical agents with potent anti-cancer activity 2Health News:Clinical trial demonstrates that rilonacept significantly reduces gout flares 2Health News:Clinical trial demonstrates that rilonacept significantly reduces gout flares 3Health News:Many Teen Girls Mistakenly Think HPV Vaccines Cut Risk for All STDs 2Health News:Many Teen Girls Mistakenly Think HPV Vaccines Cut Risk for All STDs 3Health News:Research shows progress toward a genital herpes vaccine 2Health News:Research shows progress toward a genital herpes vaccine 3Health News:Novel Hepatitis C Vaccine Shows Some Early Promise 2Health News:Novel Hepatitis C Vaccine Shows Some Early Promise 3Health News:Celiac Disease in Women Linked to Depression Risk 2
... The Hoffmann® II Compact™ Upper extremity fixator ... of the distal radius by allowing independent ... One of the main goals has been ... providing total versatility and ease of use. ...
The Small External Fixator has straight or angled frames, independent pin placement, and combines easily with Large and Medium External Fixator frames....
... Fixator is now available in a convenient, ... instrumentation. The surgical technique is printed on ... , ,This fixator allows the surgeon to ... multipaner adjustments in the frame via joints ...
... Fixation System for distal radius fractures allows ... length and rotation. The unique wrist lock ... into extension without losing fracture reduction. Post-op ... the surgeons office. Priced competitively and sold ...
Medicine Products: